Informations générales (source: ClinicalTrials.gov)
New Diagnosis or Prognosis Biomarkers for Alzheimer's Disease: Biobank of CSF Collected as Part of Differential Diagnosis of Dementia (BioAD)
Observational
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
juillet 2013
décembre 2050
29 juin 2024
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria
but also on complementary examinations to confirm a physiopathological process of AD. In
complex cases, lumbar punction could be necessary in order to measure Aβ peptides and
Total and phosphorylated Tau but new biomarkers could be useful. The main objective of
this project is to conserve these cerebrospinal fluids, collected in usual practice in
order to validate new biomarkers for diagnosis, prognosis or therapeutic following of
Alzheimer's disease and other dementia.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHRU De Nancy - 54500 - Nancy - Grand Est - France | Catherine MALAPLATE | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Lumbar punction collected in usual practice in the context of dementia diagnosis
- Lumbar punction collected in usual practice in the context of dementia diagnosis
- Absence of consent